Nabila (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Nabila, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Nabila as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Moderate to severe Alzheimer’s disease: helps maintain cognition and daily functioning. - Alzheimer’s disease combined with a cholinesterase inhibitor: may provide additional cognitive benefit. - Behavioral disturbances in Alzheimer’s disease: can reduce agitation and improve patient comfort.

Memantine may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare skin blistering condition.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: dose may need adjustment based on kidney function. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rate. - Concomitant use with other NMDA antagonists: avoid combined therapy. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture.

Memantine can interact with other medications, requiring vigilance.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Ketamine: combined NMDA blockade can cause severe CNS depression. - Other NMDA antagonists: avoid concurrent use due to heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effects. - Antihypertensives: monitor blood pressure for additive lowering. - Anticholinergic agents: may worsen confusion or cognitive impairment.